Elie Dolgin’s recent article in Nature Biotechnology explains why the apparent failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development – including work by SRF’s Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.
Send In The Senolytics
- By SRF staff
- November 17, 2020
- 9:50 am
Elie Dolgin's recent article in Nature Biotechnology explains why the failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development - including work by SRF's Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.

- By SRF staff
- November 17, 2020
- 9:50 am
Share on facebook
Share on twitter
Share on reddit
Share on linkedin
Share on google
Share on email
Latest Posts:
Parabiosis: the Dilution Solution?
Michael Rae January 11, 2021 11:08 am
Send In The Senolytics
SRF staff November 17, 2020 9:50 am
Tracking Down Glucosepane
SRF staff October 6, 2020 3:19 pm
A Letter to the Economist
SRF staff September 24, 2020 2:36 am
Defatting the Streaks
SRF staff August 12, 2020 10:08 am
Which Links Must Be Broken?
SRF staff June 22, 2020 9:58 am
New 2020 Publications
SRF staff March 10, 2020 10:52 am
Staging Aging
SRF staff November 7, 2019 10:52 am
Job Opportunity: Research Assistant (Immunology)
SRF staff October 10, 2019 8:39 am
Rejuvenation Now!
SRF staff September 6, 2019 11:02 am
Vitalik’s $350,000 Donation
SRF staff January 3, 2019 2:02 am